

Press Release >

TrakCel Strengthens Board with Addition of Peter Wright

Will assist Welsh bio-tech firm through accelerated growth period

April 22, 2015

CARDIFF, WALES, UK –TrakCel, a provider of supply chain management technology for cell therapies, today announced former strategic investment director of Finance Wales Peter Wright will join the firm as a non-executive board member. He will help guide the firm through its commercial growth phase as TrakCel strives to acquire further cell therapy development clients in 2015.

Mr Wright was a strategic investment director at Finance Wales plc from 2013 until October 31, 2014, having joined as an investment director in November 2004. Previously, he held senior positions at Fortis Bank, NatWest Bank and RBS.

He joins the board as TrakCel commences its growth strategy, having completed a recent round of investment funding. Since the beginning of 2015 TrakCel has completed a series of new appointments, expanded marketing activities and acquired larger office facilities to support the growth plan.

"I believe TrakCel's innovative technology will accelerate the development of cell therapies and will have a profound impact on the advancement of healthcare." said Peter Wright. "I'm excited to join at a time when the company is aspiring to present itself on the global stage."

In 2014 TrakCel established a foothold in the biotechnology marketplace by announcing partnerships with GlaxoSmithKline and The Cell Therapy Catapult. The company is focused on growing globally in 2015, having completed a series of exhibitions and presentations and early client engagements in the first quarter.

"Peter Wright has a wealth of experience in working with small and medium sized companies in their growth phase" said Keren Winmill, Chairperson, TrakCel, "We'll be in a much stronger position as a board to steer the company as we cope with the pressures of expansion."

TrakCel will be expanding its team to support growth initiatives including roles in business development, customer support, software development and technical operations.

- ENDS -

TrakCel

TrakCel

Iain Wood, Public Relations

07500 967 391

iain.wood@trakcel.com

publicrelations@trakcel.com

About TrakCel

TrakCel's patented technology is a single solution for controlling cell therapy processes from start to finish, to help assure patient safety, enable efficient clinical study and supply chain scale-up, provide multi-site standardisation and help drive clinical adoption. The technology provides instructions to professionals in the cell therapy process, and gives stakeholders visibility of all activities in the advanced therapy medicinal products (ATMP) supply chain from patient registration and collection of cells, through logistics, storage, processing of the cells in manufacturing and return delivery to the patient. Founded in 2012, TrakCel technology has been adopted by GlaxoSmithKline. TrakCel is based in Cardiff, Wales, UK.

TrakCel Ltd.

11 Raleigh Walk

Brigantine Place

Cardiff, UK, CF10 4LN

www.trakcel.com